Top 10 Vaccines in 2013

  #10 – Pneumovax Pneumococcal infection 2013 – $653 million 2012 – $580 million Marketed by Merck and Sanofi Pasteur MSD #9 – RotaTeq Rotaviral gastroenteritis 2013 – $691 million 2012 – $648 million Marketed by Merck and Sanofi Pasteur MSD #8 – Zostavax Herpes Zoster (Shingles) 2013 – $826 million 2012 – $ N/A Marketed by Merck and Sanofi Pasteur MSD #7 – Hepatitis vaccine franchise Hepatitis A, Hepatitis B 2013 – $984 million 2012 …

Pfizer unveil results of Prevnar 13 Phase 3 study in adults with HIV

Pfizer have unveiled the results from a Phase 3 study that trialled pneumococcal vaccine Prevnar 13 in adults infected with human immunodeficiency virus (HIV). In the Phase 3, open-label, single-arm trial, 331 HIV-infected individuals aged 18 years and older who had previously received at least one dose of pneumococcal polysaccharide vaccine (PSSV) were given three doses of Prevnar 13 at …